Real-world pegcetacoplan treatment of paroxysmal nocturnal hemoglobinuria patients with an unsatisfactory response to prior therapies [0.03%]
佩乐替尼治疗对既往疗法反应不佳的阵发性夜间血红蛋白尿患者的真实世界证据
Carlos Vallejo,Carmen González,Anna Gaya et al.
Carlos Vallejo et al.
Objectives: Terminal complement inhibitors can control intravascular hemolysis in Paroxysmal Nocturnal Hemoglobinuria (PNH) patients, although the hematological response achieved may not persist, and it may become unsatis...
Distinct clinical, molecular, and treatment response profiles in primary and secondary myelofibrosis: a single-center retrospective study [0.03%]
原发性和继发性骨髓纤维化的临床、分子和治疗反应特征：一项单中心回顾性研究
Wenya Liu,Yue Ren,Yingao Liang et al.
Wenya Liu et al.
Background: Myelofibrosis (MF) includes primary myelofibrosis (PMF) and secondary myelofibrosis (SMF) evolving from essential thrombocythemia (ET) or polycythemia vera (PV). The clinical and molecular heterogeneity of MF ...
Sirolimus-based treatment regimens for antinuclear antibody (ANA)-positive immune thrombocytopenia: a retrospective single-center cohort study [0.03%]
他克莫司为基础的免疫抑制方案治疗抗核抗体阳性的特发性免疫性血小板减少症患者的疗效分析：单中心回顾性队列研究
Aoxue Tan,Jia Liu,Xiaoli Chen et al.
Aoxue Tan et al.
Objectives: To evaluate the efficacy and safety of sirolimus-based treatment regimens in patients with antinuclear antibody (ANA)-positive immune thrombocytopenia (ITP). ...
Relationship between major depressive disorder and venous thromboembolism: a five-ancestry genetic analysis [0.03%]
抑郁症与静脉血栓栓塞的关联：五类祖先系遗传分析
Qian Liu,Qian Jing,Jinyu Zuo et al.
Qian Liu et al.
Objectives: Major depressive disorder (MDD) and venous thromboembolism (VTE) frequently co-occur and impose substantial public health burdens. Previous Mendelian randomization (MR) studies examined their causal associatio...
The prognostic value of AQP1 in hyperbilirubinemia related to ABO hemolytic disease of the newborn [0.03%]
AQP1在ABO溶血病高胆红素血症中的预后价值研究
Zhenzhen Liu,Wei Shi,Jian Zhu et al.
Zhenzhen Liu et al.
Background: ABO hemolytic disease of the newborn (ABO-HDN) is a major cause of hyperbilirubinemia in neonates, often inducing significant elevation of serum bilirubin levels shortly after birth. ...
Lactylation and liquid-liquid phase separation related genes influence prognosis and immune characteristics of diffuse large B-cell lymphoma patients [0.03%]
乳酰化和液-液相分离相关基因影响弥漫性大B细胞淋巴瘤患者的预后和免疫特征
Sihui Chen,Zhenqi Lou,Jieyang Zhu et al.
Sihui Chen et al.
Objectives: Lactylation and liquid-liquid phase separation related genes have been reported to be associated with tumor prognosis and immunity, but their specific influence on the prognosis and immune characteristics of d...
OVCA2 acts as an oncogene in pediatric AML by negatively regulating CDKN1A to drive cell cycle progression [0.03%]
OVCA2通过抑制CDKN1A促进儿童急性髓系白血病细胞周期进展而充当致癌基因
Wanyan Jiao,Saisai Cheng,Xiao Yang et al.
Wanyan Jiao et al.
Objectives: Pediatric acute myeloid leukemia (AML) is biologically distinct from adult AML and carries a poor prognosis. OVCA2, a serine hydrolase with context-dependent roles, has unknown function in AML. We aimed to inv...
First report of a rare hemoglobin variant in the Chinese population: clinical and hematological characteristics of Hb Norton [HBA2:c.217C>G] and its impact on HbA1c testing: a case report [0.03%]
首例罕见中国汉族人诺顿血红蛋白病病例报告及对糖化血红蛋白检测的影响：病例报告
Jian Shang,Zirui Cao,Weidong Chen et al.
Jian Shang et al.
Objectives: Hemoglobin (Hb) variants are a common type of single-gene disorder and a frequent source of interference in HbA1c testing. Here, we first report a rare Hb variant, Hb Norton [HBA2:c.217C>G], in the Chinese pop...
XPO1 inhibitor selinexor suppresses homologous recombination by inhibiting E2F7 nuclear export in acute myeloid leukemia [0.03%]
XPO1抑制剂塞利尼索通过抑制E2F7核出口抑制急性髓系白血病同源重组
Chunli Xu,Dandan Wang,Ruiqi Chen et al.
Chunli Xu et al.
Objectives: Aberrant nucleocytoplasmic transport mediated by Exportin 1 (XPO1) contributes to leukemogenesis, yet the molecular basis underlying the limited efficacy of the XPO1 inhibitor Selinexor in acute myeloid leukem...
In-hospital and short-term outcomes in patients with atrial fibrillation undergoing chimeric antigen receptor-T cell therapy [0.03%]
经嵌合抗原受体T细胞治疗的心房颤动患者的院内及短期预后
Nan Zhao,Wen Li,Qian Chen et al.
Nan Zhao et al.
Background: Chimeric antigen receptor T-cell (CAR-T) therapy is an innovative immunotherapy for hematologic malignancies. Cardiovascular complications associated with CAR-T therapy have also received increasing attention....